Drugs / JS201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04956926 | Jul 2021 → Jul 2023 | cancer | Shanghai Junshi Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04951947 | Jun 2023 → Dec 2024 overdue | small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04951947 ↗ |
| Route | Intravenous | “JS201 300mg i.v Q2w” NCT04951947 ↗ |